Back to mobile site

H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)

May 22, 2026 6:51 AM EDT Send to a Friend
H.C. Wainwright analyst Mitchell Kapoor reiterated a Neutral rating and $50.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login